周四，Piper Sandler对Abbott Laboratories (NYSE:ABT)股票启动了覆盖，给予超配评级，并设定131美元的目标价。 该公司强调了Abbott的强劲执行力，但指出由于与坏死性小肠结肠炎（NEC）相关的持续诉讼，该股票年初至今表现不佳。尽管如此，该公司认为，诉讼可能造成的损失已经反映在当前的股价中。 根据Piper Sandler的说法，Abbott Laborat ...

Let's not forget about Abbott Laboratories' impressive streak of 52 consecutive annual dividend increases, which also makes ...

This was the stock's third consecutive day of losses.

Piper Sandler initiates coverage on Abbott with an Overweight rating, citing its diversified business model, strong medtech ...

Cardiovascular disease is rising, and Abbott Laboratories is well-positioned in the CVD treatment space. Read why I'm neutral ...

AUSTIN - Governor Greg Abbott announced a reward of up to $5,000 for information leading to the identification and arrest of ...

根据最近的SEC文件显示，Abbott Laboratories (NYSE:ABT)的董事长兼首席执行官Robert B. Ford已出售了其在公司的大量股份。2024年9月12日，Ford以116.04美元至117.29美元的价格区间出售了共计141,679股，交易总额超过1600万美元。

9月19日，美股市场的医疗保健股雅培(Abbott Laboratories, ABT)遭遇回调，盘中股价下跌1.22%，报113.475美元/股，成交量达到2.9亿美元。这一波动引起投资者的广泛关注，尤其是在即将公布财务报告的背景下，市场对雅培的未来表现充满期待。 近期财务数据显示，截至2024年6月30日，雅培的收入总额达到203.41亿美元，同比增长3.12%。不过，归属于母公司的净利润为2 ...

依据2024年病人监护设备市场报告给出的统计与预测数据显示，2023年，全球与中国病人监护设备市场规模达到 亿元（人民币）与 亿元。在预测期间内，预计全球病人监护设备市场将以 %的复合年增长率增长，并预测至2029年全球病人监护设备市场总规模将会达到 ...

Fintel reports that on September 19, 2024, Piper Sandler initiated coverage of Abbott Laboratories ( LSE:0Q15) with a Overweight recommendation. What is the Fund Sentiment?

Fintel reports that on September 19, 2024, Piper Sandler initiated coverage of Abbott Laboratories ( NYSE:ABT) with a Overweight recommendation.

Adam Maeder, an analyst from Piper Sandler, has initiated a new Buy rating on Abbott Laboratories (ABT). Adam Maeder has given his Buy rating ...